ProMIS Neurosciences, Inc. (PMN)
NASDAQ: PMN · Real-Time Price · USD
0.6401
-0.0701 (-9.87%)
At close: Apr 3, 2025, 4:00 PM
0.6634
+0.0233 (3.63%)
Pre-market: Apr 4, 2025, 6:01 AM EDT
ProMIS Neurosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
7
Market Cap
20.92M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
PMN News
- 4 days ago - ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights - GlobeNewsWire
- 11 days ago - ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference - GlobeNewsWire
- 22 days ago - ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting - GlobeNewsWire
- 24 days ago - ProMIS Neurosciences to Participate in the 37th Annual Roth Conference - GlobeNewsWire
- 5 weeks ago - ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease - GlobeNewsWire
- 2 months ago - ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference - GlobeNewsWire
- 2 months ago - ProMIS Neurosciences Issues Letter to Shareholders - GlobeNewsWire
- 5 months ago - ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights - GlobeNewsWire